He discusses pathways that could play a role in helping solve this problem, including combinations with ADCs, STING and CD47, and work by...

Matt Biegler summarizes a breast cancer panel from the conference and talks about recent data from Relay and upcoming data from Gilead....

She describes the properties that she believes give NK cells an edge over T-cells, and discussed work in cell therapies, engagers, and...

John Heymach gives an overview of how TKIs are progressing in the EGFR and HER2 space, his thoughts on the recent VEGF x PD1 data that...

Ferran Prat, who is in charge of external innovation at MD Anderson, talks about what makes for a good partnership, and he also describes...

Professor Lannfelt recounts the history of researching amyloid beta and explains why he thinks it is vital to target amyloid beta...

Chris Molineaux kicks off this annual meeting of the Pennsylvania life sciences ecosystem and highlights this year's partnering theme.

He introduces us to Pareto and the conference, and highlights BioInvent, Oculis, Camurus, Vicore Pharma, and Calliditas.

He describes keys such as having a U.S. listing, keeping powerpoint presentations concise, and following the actions of a peer group.

He covers presentations from Incyte, Genmab, Amgen, and Bristol Myers.

She describes the areas of women's health her firm is focused on, and the importance of getting payers on board.

He highlights things to watch at this year's conference such as PD1xVEGF, PRMT5, TIGIT, and numerous ADCs.

Rajesh Kumar, HSBC's head of life sciences and healthcare equity research in London, talks Merck, Roche, Novo Nordisk, Lilly, Bayer, and...

Known widely as RNAiAnalyst on twitter, he discusses antisense, RNAi, CRISPR, base editing, ADAR, splicing, and more.

PSCC President Eric Vivier describes the facilities that are being built and other pillars of support that the cluster can offer cancer...

He describes Sofinnova Partners and its numerous investment strategies, the hidden gems of research expertise that can be found...

Emily Fang introduces us to InFocus, a company working on small molecule RNA modulation, and shares her thoughts on the local biotech...

He describes the results of this study, which tested KERENDIA in patients with mildly reduced or preserved ejection fraction.

She describes the study results, offers her opinion on where vutrisiran may enter the treatment paradigm, and shares more about ATTR-CM...

He discusses the sector's IPO activity YTD, what we might expect through the end of the year, and what types of companies have the best...